ERAS (Erasca) Cash-to-Debt : 5.75 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Erasca Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Erasca's cash to debt ratio for the quarter that ended in Dec. 2024 was 5.75.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Erasca could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Erasca's Cash-to-Debt or its related term are showing as below:

ERAS' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.59 Med: 10.78 Max: 39.75
Current: 5.75

During the past 6 years, Erasca's highest Cash to Debt Ratio was 39.75. The lowest was 5.59. And the median was 10.78.

ERAS's Cash-to-Debt is ranked worse than
53.71% of 1482 companies
in the Biotechnology industry
Industry Median: 7.525 vs ERAS: 5.75

Erasca Cash-to-Debt Historical Data

The historical data trend for Erasca's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Erasca Cash-to-Debt Chart

Erasca Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

39.75

22.06

7.91

5.59

5.75

Erasca Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															5.59	5.42	7.57	6.02	5.75

Competitive Comparison of Erasca's Cash-to-Debt

For the Biotechnology subindustry, Erasca's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Erasca's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Erasca's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Erasca's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Erasca Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Erasca's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	298.309	/	(4.619	+	47.27)
	=	5.75

Erasca's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	298.309	/	(4.619	+	47.27)
	=	5.75

Erasca (NAS:ERAS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Erasca Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Erasca's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Erasca Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Erasca Inc (NAS:ERAS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

3115 Merryfield Row, Suite 300, San Diego, CA, USA, 92121

Website

https://www.erasca.com

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Executives

Alexander W. Casdin	director	C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
Jonathan E Lim	director, 10 percent owner, officer: See Remarks	11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121
Start Valerie Denise Harding	director	C/O IGNYTA, INC., 11111 FLINTKOTE AVE., SAN DIEGO CA 92121
Shannon Morris	officer: Chief Medical Officer	C/O ERASCA, INC., 3115 MERRYFIELD ROW, SUITE 300, SAN DIEGO CA 92121
James Arthur Bristol	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Cormorant Asset Management, Lp	director	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp	director	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	director	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	director	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Jean I Liu	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Pratik S Multani	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Julie Hambleton	director	C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Ebun Garner	officer: General Counsel	C/O ALPHATEC HOLDINGS, INC., 2051 PALOMAR AIRPORT ROAD, CARLSBAD CA 92011
Arch Venture Partners X Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Lim Conyee T.	10 percent owner	C/O ERASCA, INC., 10835 ROAD TO THE CURE #140, SAN DIEGO CA 92121